Metabolomics identifies drug targets for treating major depressive disorder, highlighting lipid-redox interactions and metabolic networks.
The MDD metabotype represents a cohesive metabolic network that is associated with the NIMETOX pathogenesis of MDD. Metabolomics provides a comprehensive foundation for subtyping and precision psychiatry. Lipoxygenase-15, lipotoxicity, phospholipase A₂, and lipid-redox intersections might be important drug targets to treat MDD.
No takes yet. Share an insight, caveat, or question.
Maes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: